GV led Chroma Medicine's Series B financing round, which the biotech will apply toward epigenetic medicines that could offer advantages over other editing technologies. Other recent financings include rounds from Cargo Therapeutics and Transcend Therapeutics.
Chroma Medicine is developing epigenetic therapies that turn genes on or off. The biotech startup has emerged from stealth mode backed by a $125 million Series A round of funding.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
MorphoSys is acquiring Constellation Pharmaceuticals and its late-stage myelofibrosis drug in a deal that values the epigenetics biotech at $1.7 billion. Germany-based MorphoSys will finance the acquisition with cash from a separate $2 billion deal with drug royalty acquirer Royalty Pharma.
Company will pursue RNA-modifying protein targets to discover and develop new treatments in oncology.
Seed is a next-generation sequencing test that identifies signs of DNA methylation in sperm as the result of aging, smoking, pollution and other factors.
The global market for fertility medicine is now $30-40 billion per year, but many continue to view it as a women's health problem. Episona hopes to change that, with its epigenetics-based male fertility test.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Along with a $21 million Series B, the epigenetics startup is bringing a new CEO - Geoff Smith, former site lead and vice president of product development at Illumina.
We all know that exercise reduces our risk of diabetes and heart disease, let alone weight loss, but what’s really going on underneath it all? A new study explains that this kind of activity actually changes the shape and function of our genes. It’s not a simple task to understand the function of the human […]
Women with breast cancer virtually never die from their primary tumor. Rather, the vast majority – nearly 90 percent – of solid tumor deaths happen because it’s metastasized through the blood, said Oscar Bronsther, CEO of diagnostics company MetaStat. The company is developing diagnostics for metastatic breast cancer, so physicians can determine whether surgery and local radiation will suffice […]
A company in the burgeoning field of epigenetics has raised about $5 million in debt financing, right on the heels of refiling for an initial public offering. Syndax Pharmaceuticals, a late-stage Massachusetts biotech, postponed an IPO from June but, according to an August 28 filing, still plans to raise $60 million when it goes public. It’s offering […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Right on the heels of embarking on two new Phase 1 trials, epigenetics player Constellation Pharma has raised $5 million in an internal round from existing investors – a solid chunk of change. “It’s just the amount we needed to top off our balance sheet in order to take the company to a decision point for […]